FDA extends review of Biogen’s multiple sclerosis drug
By Esha Dey | Reuters (Reuters) – Biotechnology company Biogen Idec Inc said U.S. health regulators extended by three months the review date…
Biogen releases more positive data for oral MS drug
By Julie Donnelly, Boston Business Journal Biogen Idec (NASDAQ: BIIB) is awaiting approval from the U.S. Food and Drug Administration for…
Stuart Schlossman
Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis
October 15, 2012 Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress…
Stuart Schlossman
THE NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PIVOTAL DATA DEMONSTRATING EFFICACY AND SAFETY OF ORAL BG-12 (DIMETHYL FUMARATE) IN MULTIPLE SCLEROSIS
Sept 19, 2012 The New England Journal of Medicine Publishes Pivotal Data Demonstrating Efficacy and Safety of Oral BG-12 (Dimethyl…
Stuart Schlossman
Another Experimental MS Pill Continues to Show Promise
WebMD Medical News By Salynn Boyles Reviewed by Louise Chang, MD Sept. 19, 2012 — An experimental pill is showing promise for…
Stuart Schlossman
Aubagio, a once a day pill for MS, Now FDA Approved
The U.S. Food and Drug Administration today approved Aubagio (teriflunomide), a once-a-day tablet for the treatment of adults with relapsing…
Stuart Schlossman
Sanofi multiple sclerosis pill wins U.S. approval
Sep 13, 2012 11:20am EDT (Reuters) – Sanofi SA has won U.S. approval for its multiple sclerosis (MS) pill Aubagio,…
Stuart Schlossman
Oral pill that treats multiple sclerosis to be made available to Scots on NHS
Sept 11, 2012 THE world’s first pill to treat multiple sclerosis is to be given to patients in Scotland on…
Stuart Schlossman
Patients must be monitored after taking first Oral dose of MS drug: Health Canada
Aug 24, 2012 OTTAWA – The manufacturer of a drug used to treat multiple sclerosis is issuing new safety recommendations…
Stuart Schlossman
Information on BG-12 from an MS Peers’ blog
BG-12 BG-12 (BG00012, Dimethyl Fumarate) is an investigational oral therapy in Phase III clinical development as a monotherapy for the…
Stuart Schlossman
